Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.37 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.37 |
| ▸ | TSPO | P30536 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4969418 | 0.91 | FFAR1 (0.45) | KCNH2LMNAMEN1ALDH1A1KMT2A | |
| SCHEMBL4972590 | 0.88 | PPARA (0.43) | KCNH2LMNAMEN1ALDH1A1KMT2A | |
| SCHEMBL2086110 | 0.84 | KCNH2 (0.44) | KCNH2LMNAPTPN1SYKALDH1A1 | |
| SCHEMBL4970602 | 0.81 | FFAR1 (0.43) | KCNH2FFAR1 | |
| SCHEMBL5508217 | 0.81 | MEN1 (0.40) | LMNASYKMEN1ALDH1A1KMT2A | |
| SCHEMBL4971865 | 0.79 | FFAR1 (0.56) | FFAR1 | |
| SCHEMBL4968600 | 0.79 | FFAR1 (0.50) | LMNAMEN1ALDH1A1KMT2AHSD17B2 | |
| SCHEMBL4970094 | 0.79 | FFAR1 (0.42) | FFAR1 | |
| SCHEMBL4969393 | 0.78 | AKR1C3 (0.41) | KCNH2PTPN1KMT2AAKR1C3FFAR1 | |
| SCHEMBL4967970 | 0.78 | AKR1C3 (0.40) | KCNH2PTPN1AKR1C3FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1781274-B1 | NOVEL BIAROMATIC COMPOUNDS WHICH ACTIVATE RECEPTORS OF PPAR TYPE AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RES & DEV (FR) | 2008-11-05 | — | — | EP | claimed |
| US-20070207175-A1 | Biaromatic compound activators of PPARgamma receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-09-06 | — | — | US | claimed |
| US-20070207175-A1 | Biaromatic compound activators of PPARgamma receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070207175-A1 | Biaromatic compound activators of PPARgamma receptors and cosmetic/pharmaceutical compositions comprised thereof | PPARG, PPARA, PPARD | KCNH2 4097/4885LMNA 2446/4885PTPN1 1201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.